{
  "id": 327411,
  "title": "Hypera Q2 Profit Rises 15% to US$96 Million",
  "url": "https://urgent.news/2026/08/08/hypera-q2-profit-rises-15-to-us-96-million",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-08T21:32:50.000Z",
  "source": {
    "name": "The Rio Times",
    "slug": "the-rio-times",
    "url": "https://www.riotimesonline.com/hypera-q2-2026-profit/"
  },
  "original_language": "en",
  "account": "Hypera, a Brazilian pharmaceutical company, reported a 15% increase in net profit for the second quarter of 2026, reaching R$490.0 million (US$96.4 million). The profit growth was driven by wider gross margins and disciplined working-capital management, which offset increased marketing and selling expenses. Net revenue grew 8.5% year-on-year to R$2.3367 billion (US$459.7 million), while EBITDA from continuing operations rose 4.1% to R$754.9 million (US$148.5 million). The company's pharmacy sales increased 7.6% in the quarter, outpacing the market by 1.4 percentage points. Gross margin improved by 1.7 percentage points to 61.8%, reflecting a more profitable product mix weighted towards branded generics and consumer health. Earnings per share from continuing operations reached R$0.70 (US$0.14) for the quarter. The company's free cash flow was R$637.8 million (US$125.5 million), with net debt at R$7.482 billion (US$1.47 billion) and a debt-to-EBITDA ratio of 2.1 times. Hypera's strong performance highlights the recovery's breadth, with cumulative net revenue and profit reaching R$4.35448 billion (US$856.7 million) and R$837.08 million (US$164.7 million), respectively.",
  "summary": "Hypera posted Q2 2026 net profit of R$490 million, up 15%, on net revenue of R$2.34 billion. Margins widened and cash generation covered all capex. 149. The post Hypera Q2 Profit Rises 15% to US$96 Million appeared first on The Rio Times .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}